King Pharmaceuticals Inc. said Monday it resubmitted its application to the Food and Drug Administration for the abuse-resistant painkiller Remoxy.
Remoxy is similar to Purdue Pharma LP’s OxyContin. Both are designed to treat pain by slowly releasing the narcotic oxycodone. But the time-release mechanism on OxyContin can be defeated if the drug is crushed or dissolved, allowing users to get a high similar to what they can get from heroin.
The Food and Drug Administration has held up approval of Remoxy and requested more proof that it cuts down on abuse. The resubmitted application has a six-month review cycle, King said.
Pain Therapeutics Inc. is King’s partner on Remoxy.